The grant provides external validation and modest non-dilutive funding for an expanded clinical program. The key catalyst remains the Phase 2b SAFEGUARD data readout. Monitor enrollment updates and any future data releases from PRISE-hATG.
Price Chart
Executive Summary
SAB Biotherapeutics announced that Breakthrough T1D awarded a grant to support the PRISE-hATG study evaluating SAB-142 in Stage 3 type 1 diabetes patients 100 days to 2 years from diagnosis. The investigator-led study extends the clinical program beyond the typical 100-day window and complements the ongoing Phase 2b SAFEGUARD trial. SAB BIO will co-fund the study; the grant amount was not disclosed.
Key Facts
- Breakthrough T1D awarded a grant to Dr. Michael Haller at University of Florida for the PRISE-hATG study of SAB-142.
- PRISE-hATG evaluates SAB-142 in Stage 3 T1D patients 100 days to 2 years from diagnosis, extending beyond the typical 100-day window.
- The study is randomized, double-blind, placebo-controlled and harmonized with the Phase 2b SAFEGUARD trial.
- SAB BIO will co-fund the study; grant amount not disclosed.
Financial Impact
Grant amount undisclosed; SAB BIO co-funds the study. No revenue or earnings impact.
Risk Factors
- Clinical trial risk — SAB-142 may fail to meet endpoints in PRISE-hATG or SAFEGUARD.
- Competition from approved T1D therapies (e.g., teplizumab) and other pipeline candidates.
- Cash burn — co-funding adds to expenses; additional financing may be needed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-296936 |
| Document: sabs-ex99_1.htm | 0001193125-26-296936 |
| Document: 0001193125-26-296936-index-headers.html | 0001193125-26-296936 |
| Document: 0001193125-26-296936-index.html | 0001193125-26-296936 |
| Document: 0001193125-26-296936.txt | 0001193125-26-296936 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 7, 2026 12w ago | 8-K | $3.90 $3.17 | ▼ −18.72% | ▼ −20.71% | $2.98 (−23.59%) |
May 29, 2026 18w ago | Press Release | $3.60 $3.62 | ▲ +0.56% | ▼ −0.63% | $2.98 (−17.22%) |
May 12, 2026 20w ago | Press Release | $3.62 $3.85 | ▼ −6.35% | ▼ −1.97% | $2.98 (+17.68%) |
Mar 19, 2026 28w ago | Press Release | $3.75 $3.90 | ▲ +4.00% | ▼ −10.42% | $2.98 (−20.53%) |
Mar 19, 2026 28w ago | 8-K | $3.78 $3.90 | ▼ −3.17% | ▲ +11.17% | $2.98 (+21.16%) |
Mar 18, 2026 28w ago | Press Release | $3.70 $3.38 | ▲ +8.65% | ▲ +20.17% | $2.98 (+19.46%) |
Mar 17, 2026 28w ago | Press Release | $3.70 $3.38 | ▲ +8.65% | ▲ +20.17% | $2.98 (+19.46%) |
Mar 10, 2026 29w ago | Press Release | $4.10 $3.36 | ▼ −18.05% | ▼ −29.73% | $2.98 (−27.32%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access